Search

Your search keyword '"Hasselbalch, Steen"' showing total 1,099 results
Start Over Author "Hasselbalch, Steen"
1,099 results on '"Hasselbalch, Steen"'

1. Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns

Author

Knecht, Luisa, Dalsbøl, Katrine, Simonsen, Anja Hviid, Pilchner, Falk, Ross, Jean Alexander, Winge, Kristian, Salvesen, Lisette, Bech, Sara, Hejl, Anne-Mette, Løkkegaard, Annemette, Hasselbalch, Steen G, Dodel, Richard, Aznar, Susana, Waldemar, Gunhild, Brudek, Tomasz, and Folke, Jonas

Published
2024
Full Text
View/download PDF

2. Computerized decision support to optimally funnel patients through the diagnostic pathway for dementia

Author

van Gils, Aniek M., Tolonen, Antti, van Harten, Argonde C., Vigneswaran, Sinthujah, Barkhof, Frederik, Visser, Leonie N. C., Koikkalainen, Juha, Herukka, Sanna-Kaisa, Hasselbalch, Steen Gregers, Mecocci, Patrizia, Remes, Anne M., Soininen, Hilkka, Lemstra, Afina W., Teunissen, Charlotte E., Jönsson, Linus, Lötjönen, Jyrki, van der Flier, Wiesje M., and Rhodius-Meester, Hanneke F. M.

Published
2024
Full Text
View/download PDF

21. Differential Lipid Signatures of Lumbar and Cisternal Cerebrospinal Fluid.

Author

Toft-Bertelsen, Trine L., Andreassen, Søren Norge, Norager, Nicolas H., Simonsen, Anja Hviid, Hasselbalch, Steen Gregers, Juhler, Marianne, and MacAulay, Nanna

Subjects
LIQUID chromatography-mass spectrometry, PHOSPHATIDIC acids, SPINAL cord, LIPIDOMICS, MASS spectrometry
Abstract

Background: The molecular composition of cerebrospinal fluid (CSF) is often used as a key indicator of biochemical alterations within distinct brain and spinal cord fluid compartments. The CSF protein content in lumbar CSF samples is widely employed as a biomarker matrix for diagnosing brain-related pathological conditions. CSF lipid profiles may serve as promising complementary diagnostics, but it remains unresolved if the lipid distribution is consistent along the neuroaxis. Methods: The lipid composition was determined with liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in cisternal CSF obtained from healthy subjects undergoing preventive surgery of an unruptured aneurism (n = 11) and lumbar CSF obtained from individuals referred for the clinical evaluation of cognitive dysfunction but subsequently cleared and deemed healthy (n = 19). Results: We reveal discernible variations in lipid composition along the neuroaxis, with a higher overall lipid concentration in cisternal CSF, although with different relative distributions of the various lipid classes in the two compartments. The cisternal CSF contained elevated levels of most lipid classes, e.g., sphingomyelins, lysophosphatidylcholines, plasmenylphosphatidylcholines, phosphatidic acids, and triacylglycerols, whereas a few select lipids from the classes of fatty acids, phosphatidylcholines, amides and plasmenylphosphatidylethanolamines were, oppositely, elevated in the lumbar CSF pool. Conclusions: The distinct lipid distribution along the neuroaxis illustrates that the molecular constituents in these two CSF compartments are not uniform. These findings emphasize the necessity of establishing a lumbar lipid index for the accurate interpretation of the cranial CSF lipid profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Membrane transporters control cerebrospinal fluid formation independently of conventional osmosis to modulate intracranial pressure

Author

Oernbo, Eva K., Steffensen, Annette B., Razzaghi Khamesi, Pooya, Toft-Bertelsen, Trine L., Barbuskaite, Dagne, Vilhardt, Frederik, Gerkau, Niklas J., Tritsaris, Katerina, Simonsen, Anja H., Lolansen, Sara D., Andreassen, Søren N., Hasselbalch, Steen G., Zeuthen, Thomas, Rose, Christine R., Kurtcuoglu, Vartan, and MacAulay, Nanna

Published
2022
Full Text
View/download PDF

27. Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study

Author

Svart, Katrine, primary, Korsbæk, Johanne Juhl, additional, Jensen, Rigmor Højland, additional, Parkner, Tina, additional, Knudsen, Cindy Søndersø, additional, Hasselbalch, Steen Gregers, additional, Hagen, Snorre Malm, additional, Wibroe, Elisabeth Arnberg, additional, Molander, Laleh Dehghani, additional, and Beier, Dagmar, additional

Published
2024
Full Text
View/download PDF

34. The Center for Integrated Molecular Brain Imaging (Cimbi) database

Author

Knudsen, Gitte M, Jensen, Peter S, Erritzoe, David, Baaré, William FC, Ettrup, Anders, Fisher, Patrick M, Gillings, Nic, Hansen, Hanne D, Hansen, Lars Kai, Hasselbalch, Steen G, Henningsson, Susanne, Herth, Matthias M, Holst, Klaus K, Iversen, Pernille, Kessing, Lars V, Macoveanu, Julian, Madsen, Kathrine Skak, Mortensen, Erik L, Nielsen, Finn Årup, Paulson, Olaf B, Siebner, Hartwig R, Stenbæk, Dea S, Svarer, Claus, Jernigan, Terry L, Strother, Stephen C, and Frokjaer, Vibe G

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Research, Depression, Neurosciences, Brain Disorders, Mental Health, Biomedical Imaging, Neurological, Mental health, Good Health and Well Being, Biological Specimen Banks, Biomarkers, Computer Security, Databases, Factual, Healthy Volunteers, Humans, Information Dissemination, Magnetic Resonance Imaging, Mental Disorders, Molecular Imaging, Neuroimaging, Neuropsychological Tests, Quality Control, Receptors, Serotonin, Medical and Health Sciences, Psychology and Cognitive Sciences, Neurology & Neurosurgery, Biomedical and clinical sciences, Health sciences
Abstract

We here describe a multimodality neuroimaging containing data from healthy volunteers and patients, acquired within the Lundbeck Foundation Center for Integrated Molecular Brain Imaging (Cimbi) in Copenhagen, Denmark. The data is of particular relevance for neurobiological research questions related to the serotonergic transmitter system with its normative data on the serotonergic subtype receptors 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4 and the 5-HT transporter (5-HTT), but can easily serve other purposes. The Cimbi database and Cimbi biobank were formally established in 2008 with the purpose to store the wealth of Cimbi-acquired data in a highly structured and standardized manner in accordance with the regulations issued by the Danish Data Protection Agency as well as to provide a quality-controlled resource for future hypothesis-generating and hypothesis-driven studies. The Cimbi database currently comprises a total of 1100 PET and 1000 structural and functional MRI scans and it holds a multitude of additional data, such as genetic and biochemical data, and scores from 17 self-reported questionnaires and from 11 neuropsychological paper/computer tests. The database associated Cimbi biobank currently contains blood and in some instances saliva samples from about 500 healthy volunteers and 300 patients with e.g., major depression, dementia, substance abuse, obesity, and impulsive aggression. Data continue to be added to the Cimbi database and biobank.

Published
2016

35. The cingulate island sign in a mixed memory clinical cohort:Prevalence and diagnostic accuracy

Author

Feng, Linda Ruohua, Waldemar, Gunhild, Hasselbalch, Steen Gregers, Vogel, Asmus, Henriksen, Otto Mølby, Law, Ian, Frederiksen, Kristian Steen, Feng, Linda Ruohua, Waldemar, Gunhild, Hasselbalch, Steen Gregers, Vogel, Asmus, Henriksen, Otto Mølby, Law, Ian, and Frederiksen, Kristian Steen

Abstract

Introduction Visual rating of the cingulate island sign (CIS) on [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) has a high specificity for dementia with Lewy bodies (DLB) in selected cohorts such as DLB versus Alzheimer's disease (AD). In a mixed memory clinical population this study aimed to uncover the prevalence of CIS, the diagnostic accuracy for DLB, and the relationship between CIS and disease severity. Methods CIS on [18F]FDG-PET was retrospectively assessed with the visual CIS rating scale (CISRs) in 1000 patients with a syndrome diagnosis of mild cognitive impairment (MCI) or dementia with no restrictions in etiological diagnosis. Results In this cohort 24.3 % had a CISRs score ≥1 and 3.5 % had a CISRs score = 4. The prevalence of a CISRs score ≥1 was highest in DLB (74.0 %, n = 57). A CISRs score ≥1 was present in at least 9 % in other diagnostic groups. The prevalence of CIS across disease severities showed no statistically significant difference (p = 0.23). To differentiate DLB from non-DLB the optimal cut-off was a CISRs score ≥1 (balanced accuracy = 77.1 %) in MCI/mild dementia and a CISRs score ≥2 (balanced accuracy = 80.6 %) in moderate/severe dementia. The positive predictive value of a CISRs score = 4 for DLB was 57.7 % in MCI/mild dementia and 33.3 % in moderate/severe dementia. Conclusion The CISRs is useful in differentiating DLB from other etiologies in a mixed memory clinical population. Balanced accuracy and positive predictive value may vary across disease severities in the population studied., Introduction: Visual rating of the cingulate island sign (CIS) on [18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) has a high specificity for dementia with Lewy bodies (DLB) in selected cohorts such as DLB versus Alzheimer's disease (AD). In a mixed memory clinical population this study aimed to uncover the prevalence of CIS, the diagnostic accuracy for DLB, and the relationship between CIS and disease severity. Methods: CIS on [18F]FDG-PET was retrospectively assessed with the visual CIS rating scale (CISRs) in 1000 patients with a syndrome diagnosis of mild cognitive impairment (MCI) or dementia with no restrictions in etiological diagnosis. Results: In this cohort 24.3 % had a CISRs score ≥1 and 3.5 % had a CISRs score = 4. The prevalence of a CISRs score ≥1 was highest in DLB (74.0 %, n = 57). A CISRs score ≥1 was present in at least 9 % in other diagnostic groups. The prevalence of CIS across disease severities showed no statistically significant difference (p = 0.23). To differentiate DLB from non-DLB the optimal cut-off was a CISRs score ≥1 (balanced accuracy = 77.1 %) in MCI/mild dementia and a CISRs score ≥2 (balanced accuracy = 80.6 %) in moderate/severe dementia. The positive predictive value of a CISRs score = 4 for DLB was 57.7 % in MCI/mild dementia and 33.3 % in moderate/severe dementia. Conclusion: The CISRs is useful in differentiating DLB from other etiologies in a mixed memory clinical population. Balanced accuracy and positive predictive value may vary across disease severities in the population studied.

Published
2024

36. Differentiating anti-IgLON5 disease and Lewy body dementia:a systematic review

Author

McWilliam, Oskar, Gramkow, Mathias H., Blaabjerg, Morten, Clemmensen, Frederikke Kragh, Hasselbalch, Steen G., Frederiksen, Kristian Steen, McWilliam, Oskar, Gramkow, Mathias H., Blaabjerg, Morten, Clemmensen, Frederikke Kragh, Hasselbalch, Steen G., and Frederiksen, Kristian Steen

Abstract

Background Anti-IgLON5 disease is a rare but potentially reversible cause of cognitive impairment, sleep disturbances, dysautonomia, and movement disorders. It is an autoimmune encephalitis which, due to its insidious onset, could mimic neurodegenerative disorders, and multiple symptoms overlap with those seen in dementia with Lewy bodies (DLB). We hypothesized that the symptomatology and findings in patients with anti-IgLON5 disease overlapped with that of DLB. Objectives To assess the commonality of features in anti-IgLON5 disease and DLB and identify potential red flags for anti-IgLON5 disease in patients undergoing diagnostic evaluation for DLB. Methods We searched in MEDLINE, Web of Science, and Embase from inception on December the 8th, 2022 with the search term “IgLON5”. We performed a systematic review of case reports and case series of anti-IgLON5 disease, and two reviewers independently extracted data on symptoms and findings. Frequencies of symptoms were compared with consensus criteria for DLB. Results We included 57 studies with 127 individual case reports of anti-IgLON5 disease (mean age 63 years at diagnosis, median symptom duration 2 years). Cognitive dysfunction was reported in 45% of cases, REM—sleep behavioral disorder in 15%, and 14% had parkinsonism. Respiratory insufficiency was reported in 37%, and bulbar symptoms in 67%. Conclusions We found a significant overlap between anti-IgLON5 disease and DLB. We propose that anti-IgLON5 disease should be considered in young patients with DLB with chorea, gaze palsy, early dysphagia, or prominent respiratory symptoms. Our study contributes to the emerging knowledge on symptoms and biomarkers in anti-IgLON5 disease., Background: Anti-IgLON5 disease is a rare but potentially reversible cause of cognitive impairment, sleep disturbances, dysautonomia, and movement disorders. It is an autoimmune encephalitis which, due to its insidious onset, could mimic neurodegenerative disorders, and multiple symptoms overlap with those seen in dementia with Lewy bodies (DLB). We hypothesized that the symptomatology and findings in patients with anti-IgLON5 disease overlapped with that of DLB. Objectives: To assess the commonality of features in anti-IgLON5 disease and DLB and identify potential red flags for anti-IgLON5 disease in patients undergoing diagnostic evaluation for DLB. Methods: We searched in MEDLINE, Web of Science, and Embase from inception on December the 8th, 2022 with the search term “IgLON5”. We performed a systematic review of case reports and case series of anti-IgLON5 disease, and two reviewers independently extracted data on symptoms and findings. Frequencies of symptoms were compared with consensus criteria for DLB. Results: We included 57 studies with 127 individual case reports of anti-IgLON5 disease (mean age 63 years at diagnosis, median symptom duration 2 years). Cognitive dysfunction was reported in 45% of cases, REM—sleep behavioral disorder in 15%, and 14% had parkinsonism. Respiratory insufficiency was reported in 37%, and bulbar symptoms in 67%. Conclusions: We found a significant overlap between anti-IgLON5 disease and DLB. We propose that anti-IgLON5 disease should be considered in young patients with DLB with chorea, gaze palsy, early dysphagia, or prominent respiratory symptoms. Our study contributes to the emerging knowledge on symptoms and biomarkers in anti-IgLON5 disease.

Published
2024

38. Digital Biomarkers for the Assessment of Non-Cognitive Symptoms in Patients with Dementia with Lewy Bodies: A Systematic Review.

Author

Sjaelland, Nikolai S., Gramkow, Mathias H., Hasselbalch, Steen G., and Frederiksen, Kristian Steen

Subjects
LEWY body dementia, DEMENTIA patients, BIOMARKERS, DIGITAL health, SYMPTOMS
Abstract

Background: Portable digital health technologies (DHTs) could help evaluate non-cognitive symptoms, but evidence to support their use in patients with dementia with Lewy bodies (DLB) is uncertain. Objective: 1) To describe portable or wearable DHTs used to obtain digital biomarkers in patients with DLB, 2) to assess the digital biomarkers' ability to evaluate non-cognitive symptoms, and 3) to assess the feasibility of applying digital biomarkers in patients with DLB. Methods: We systematically searched databases MEDLINE, Embase, and Web of Science from inception through February 28, 2023. Studies assessing digital biomarkers obtained by portable or wearable DHTs and related to non-cognitive symptoms were eligible if including patients with DLB. The quality of studies was assessed using a modified check list based on the NIH Quality assessment tool for Observational Cohort and Cross-sectional Studies. A narrative synthesis of data was carried out. Results: We screened 4,295 records and included 20 studies. Seventeen different DHTs were identified for assessment of most non-cognitive symptoms related to DLB. No thorough validation of digital biomarkers for measurement of non-cognitive symptoms in DLB was reported. Studies did not report on aspects of feasibility in a systematic way. Conclusions: Knowledge about feasibility and validity of individual digital biomarkers remains extremely limited. Study heterogeneity is a barrier for establishing a broad evidence base for application of digital biomarkers in DLB. Researchers should conform to recommended standards for systematic evaluation of digital biomarkers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Diagnostic performance of light reflex pupillometry in Alzheimer's disease.

Author

Gramkow, Mathias Holsey, Clemmensen, Frederikke Kragh, Sjælland, Nikolai Sulkjær, Waldemar, Gunhild, Hasselbalch, Steen Gregers, and Frederiksen, Kristian Steen

Subjects
LEWY body dementia, ALZHEIMER'S disease, RECEIVER operating characteristic curves, COGNITION disorders, PUPILLOMETRY
Abstract

Easily applied diagnostic tools such as digital biomarkers for Alzheimer's disease (AD) are urgently needed due to the recent approval of disease‐modifying therapies. We aimed to determine the diagnostic performance of hand‐held, quantitative light reflex pupillometry (qLRP) in patients with AD in a proof‐of‐concept, cross‐sectional study. Participants underwent qLRP at a university memory clinic from August 2022 to October 2023. We fitted multivariable logistic regression models with qLRP, sex, and age as predictors evaluated with area under the receiver operating characteristics curve (AUROC). In total, 107 patients with AD, 44 patients with mixed AD and vascular cognitive dysfunction (VCD), 53 patients with dementia with Lewy bodies (DLB), and 50 healthy controls (HCs) were included. Our diagnostic models showed similar discriminatory ability (AUROC range 0.74‐0.81) when distinguishing patients with AD from HCs and other dementias. The qLRP seems promising as a bedside digital biomarker to aid in diagnosing AD. Highlights: We demonstrated the diagnostic performance of qLRP in Alzheimer's disease.The diagnostic models were robust in sensitivity analyses.qLRP may assist in the bedside diagnostic evaluation of Alzheimer's disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Detecting frontotemporal dementia syndromes using MRI biomarkers

Author

Bruun, Marie, Koikkalainen, Juha, Rhodius-Meester, Hanneke F.M., Baroni, Marta, Gjerum, Le, van Gils, Mark, Soininen, Hilkka, Remes, Anne M., Hartikainen, Päivi, Waldemar, Gunhild, Mecocci, Patrizia, Barkhof, Frederik, Pijnenburg, Yolande, van der Flier, Wiesje M., Hasselbalch, Steen G., Lötjönen, Jyrki, and Frederiksen, Kristian S.

Published
2019
Full Text
View/download PDF

44. The shortened version of a web‐based cognitive test tool, cCOG, retains good accuracy in detecting mild cognitive impairment and dementia

Author

Landen, Sophie M., primary, Gils, Aniek M., additional, Handgraaf, Dédé, additional, Hasselbalch, Steen G., additional, Mecocci, Patrizia, additional, Soininen, Hilkka, additional, Tolonen, Antti, additional, Lötjönen, Jyrki, additional, Paajanen, Teemu, additional, Lemstra, Afina W., additional, Flier, Wiesje M., additional, Sikkes, Sietske A.M., additional, and Rhodius‐ Meester, Hanneke F.M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results